Clearmind Medicine Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Adi Zuloff-Shani

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	3.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Adi Zuloff-Shani's beloning veranderd ten opzichte van Clearmind Medicine's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jul 31 2024	n/a	n/a	-US$8m
Apr 30 2024	n/a	n/a	-US$7m
Jan 31 2024	n/a	n/a	-US$8m
Oct 31 2023	n/a	n/a	-US$9m
Jul 31 2023	n/a	n/a	-US$6m
Apr 30 2023	n/a	n/a	-US$7m
Jan 31 2023	n/a	n/a	-US$7m
Oct 31 2022	n/a	n/a	-US$7m
Jul 31 2022	n/a	n/a	-US$7m
Apr 30 2022	n/a	n/a	-US$7m
Jan 31 2022	n/a	n/a	-US$4m
Oct 31 2021	US$145k	US$113k	-US$3m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Adi redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de German markt.

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Adi te vergelijken met de prestaties van het bedrijf.

CEO

Adi Zuloff-Shani (55 yo)

3.3yrs

Tenure

Dr. Adi Zuloff-Shani, Ph D., serves as Member of Scientific Advisory Board at N2OFF, Inc. (formerly known as Save Foods, Inc.) since October 2021. She serves as Chief Executive Officer of Clearmind Medicin...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Adi Zuloff-Shani	Chief Executive Officer	3.3yrs	geen gegevens	geen gegevens
Alan Rootenberg	Chief Financial Officer	2.4yrs	geen gegevens	0% € 0
Mark Haden	Vice President of Business Development	3.3yrs	geen gegevens	0% € 0
Mylene Touboul	Accounting Manager	no data	geen gegevens	geen gegevens
Gilad Babchuk	Head of Strategy & Communication	2.8yrs	geen gegevens	geen gegevens
Adi Varon	Controller	no data	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CWY0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Haden	Vice President of Business Development	3.3yrs	geen gegevens	0% € 0
John Krystal	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Michael Davidson	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Alon Friedman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Wim van den Brink	Member of Scientific Advisory Board	3.1yrs	geen gegevens	geen gegevens
Oz Adler	Independent Director	2.9yrs	geen gegevens	0.0028% € 147.1
Amitai Weiss	Independent Chairman	5.3yrs	geen gegevens	0% € 0
Yehonatan Shachar	Independent Director	4.6yrs	geen gegevens	0% € 0
Gabriele Fischer	Member of Scientific Advisory Board	3.1yrs	geen gegevens	geen gegevens
Gal Yadid	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Christian Schutz	Member of Scientific Advisory Board	2.5yrs	geen gegevens	geen gegevens
Asaf Itzhaik	Director	1.9yrs	geen gegevens	geen gegevens

3.1yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CWY0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

Clearmind Medicine Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025

High number of new and inexperienced directors

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Inc. Announces Board Appointments

High number of new and inexperienced directors

Recent updates

Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025

Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment

Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression

Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities Exchange

Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration

Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million.

Clearmind Medicine Inc. has completed a Follow-on Equity Offering.

Clearmind Medicine Inc. has filed a Follow-on Equity Offering.

Clearmind Medicine Inc. has filed a Follow-on Equity Offering.

Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing Standards

Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Scisparc Ltd. Obesity Drug Showed Positive Results in A Pre-Clinical Trial

High number of new and inexperienced directors

Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based Treatment

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice

Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Clearmind Medicine Inc. announced that it expects to receive $2.25 million in funding

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use Disorder

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use Disorder

Clearmind Medicine Inc. Announces Board Appointments

Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark Office

Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based Compound

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100

Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical Trial

High number of new and inexperienced directors

Clearmind Medicine Inc. Common Shares Deleted from OTC Equity

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022

High number of new and inexperienced directors

Analyse CEO-vergoeding

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd